Please substitute the current version of the paragraph starting on page 12, line 16, and ending on page 12, line 17, with the following paragraph:

a3

Figure 11C. Sequence of oligonucleotide E16631A1 (SEQ ID NO:49) used to construct rTether-1.

Please substitute the current version of the paragraph starting on page 12, line 18, and ending on page 12, line 21, with the following paragraph:

a4

Figure 11D. Flanking sequence and PTH insert (SEQ ID NO:50). The slash marks (|) indicates the flanking regions to the left and right of the PTH insert. Sequence of oligonucleotide E16631A and its protein translation. (note DNA sequence here is same as in Figure 11C (SEQ ID NO:49).

Please substitute the current version of the paragraph starting on page 26, line 3, and ending on page 26, line 10, with the following paragraph:

a5

In another specific embodiment, this invention provides a biologically active peptide useful for the design of agonists for the PTH1R or PTH2R receptor comprising the compound S-$(L)_n$-B, wherein S is the signaling peptide PTH(1-9)(Ala Val Ser Glu Ile Gln Leu Met His (SEQ ID NO: 1)); L is the linker molecule $(Gly)_7$; and B is a binding peptide PTH(17-31)(Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val (SEQ ID NO:63)). The entire sequence being PG7: Ala Val Ser Glu Ile Gln Leu Met His Gly Gly Gly Gly Gly Gly Gly Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val (SEQ ID NO:6).

Please substitute the current version of the paragraph starting on page 26, line 11, and ending on page 26, line 19, with the following paragraph:

a6

In one specific embodiment, this invention provides a biologically active peptide useful for the design of agonists for the PTH1R or PTH2R receptor comprising the compound S-$(L)_n$-B, wherein S is the signaling peptide PTHrP(1-9)(Ala Val Ser Glu His Gln Leu Leu His (SEQ ID NO: 7)); L is the linker molecule $(Gly)_5$; and B is a binding peptide PTHrP(15-31)(Ile Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile (SEQ ID NO:8)). The entire sequence being PrPG5: Ala Val Ser Glu His Gln Leu Leu His Gly Gly Gly

a6 cont

Gly Gly (Ile Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile (SEQ ID NO:64).

Please substitute the current version of the paragraph starting on page 26, line 20, and ending on page 26, line 27, with the following paragraph:

a7

In another specific embodiment, this invention provides a biologically active peptide useful for the design of agonists for the PTH1R or PTH2R receptor comprising the compound S-$(L)_n$-B, wherein S is the signaling peptide PTHrP(1-5)(Ala Val Ser Glu His (SEQ ID NO:10)); L is the linker molecule $(Gly)_9$; and B is a binding peptide PTHrP(15-31)(Ile Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile (SEQ ID NO:8)). The entire sequence being PrPG9: Ala Val Ser Glu His Gly Gly Gly Gly Gly Gly Gly Gly Gly (Ile Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile (SEQ ID NO:65).

Please substitute the current version of the paragraph starting on page 26, line 28, and ending on page 27, line 5, with the following paragraph:

a8

In another specific embodiment, this invention provides a biologically active peptide useful for the design of agonists for the PTH1R or PTH2R receptor comprising the compound S-$(L)_n$-B, wherein S is the signaling peptide PTHrP(1-9)(Ala Val Ser Glu His Gln Leu Leu His (SEQ ID NO:7)); L is the linker molecule $(Gly)_7$; and B is a binding peptide PTHrP(17-31)(Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile (SEQ ID NO:12)). The entire sequence being PrPG7: Ala Val Ser Glu His Gln Leu Leu His Gly Gly Gly Gly Gly Gly Gly Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile (SEQ ID NO:66).

Please substitute the current version of the paragraph starting on page 30, line 1, and ending on page 30, line 3, with the following paragraph:

a9

Additionally, another embodiment of the invention may use PTH (1-11) (Ala Val Ser Glu Ile Gln Leu Met His Asn Leu (SEQ ID NO:67) where a signaling peptide ("S") is called for.

Please substitute the current version of the paragraph starting on page 50, line 16, and ending on page 51, line 2, with the following paragraph: